April 2024
CHARM2 prospective randomized controlled trial open for enrollment at UHN
This trial, funded by the Canadian Cancer Society and CIHR, will put into practice our cell-free DNA based blood test for early cancer detection.
January 1, 2023
CCS Breakthrough Team Grant Received
This grant will fund a prospective randomized controlled trial (called CHARM2), which will test the performance of our cell-free DNA blood test for early cancer detection.
July 2022
1st patient recruited in Nova Scotia
March 2022
1st patient recruited in Newfoundland and Labrador
May 2021
1st patient recruited in Quebec
December 2020
1st patient recruited at BC Cancer
September 25, 2019
1st patient recruited at Mount Sinai Hospital
Recruitment of individuals with hereditary cancer syndromes began at Mount Sinai in September 2019, following the 8th annual Lynch Syndrome Education Night.
May 2019
Qualitative findings from CHARM presented at 2019 ARCC
Leslie Oldfield, Project Manager at the Pugh Lab, presented qualitative findings in support of Aim 3 of the CHARM study (to optimize integration of ctDNA into clinical practice). These findings were presented at the 8th annual Canadian Centre for Applied Research in Cancer Control (ARCC) Conference in Halifax, Nova Scotia.
March 2019
Children’s Tumor Foundation Clinical Research Award granted
The Children’s Tumor Foundation’s mission is to drive research, expand knowledge, and advance care for the NF community. Their Clinical Research Award was granted to CHARM in order to develop cell-free DNA detection technologies in application to NF1. The tests and technologies used by CHARM will improve cancer care and health outcomes for those living with NF1.
August 2017
1st patient recruited at University Health Network into our retrospective CHARM study
Our team of Clinical Research Coordinators recruited the first patients with hereditary cancer syndromes into the CHARM study during July of 2018, starting with Princess Margaret Cancer Centre and the rest of University Health Network.